Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cordon-bleu WH2 repeat protein-like 1 (COBLL1) is an evolutionarily conserved actin-binding protein characterized by the presence of a WH2 (Wiskott–Aldrich syndrome protein homology 2) domain. It regulates actin cytoskeleton dynamics and is involved in morphogenic changes in cancer cells, promoting cell growth, migration, and morphogenesis—particularly in castration-resistant prostate cancer, where it supports androgen receptor phosphorylation and function[1]. In hematologic malignancies such as chronic lymphocytic leukemia, COBLL1 is a binding partner of the receptor ROR1 and serves as an independent prognostic biomarker, affecting cell signaling and migration. High expression of COBLL1 is associated with more aggressive disease course and alterations in cell motility and response to microenvironmental cues[1][2]. Despite these roles, no approved drugs directly target COBLL1 as of current scientific knowledge.
Not applicable (no direct targeting drugs known)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cordon-bleu WH2 repeat protein-like 1 (COBLL1).